Elucidating the inhibiting mode of AHPBA derivatives against HIV-1 protease and building predictive 3D-QSAR models

被引:42
作者
Huang, XQ
Xu, LS
Luo, XM
Fan, KN
Ji, RY
Pei, G
Chen, KX
Jiang, HL
机构
[1] Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai Inst Biol Sci, Ctr Drug Design & Discovery,State Key Lab Drug Re, Shanghai 200031, Peoples R China
[2] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Shanghai 200032, Peoples R China
[3] Fudan Univ, Dept Chem, Shanghai 2000437, Peoples R China
关键词
D O I
10.1021/jm0102710
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The Lamarckian genetic algorithm of AutoDock 3.0 has been used to dock 27 3(S)-amino-2(S)-hydroxyl-4-phenylbutanoic acids (AHPBAs) into the active site of HIV-1 protease (HIVPR). The binding mode was demonstrated in the aspects of the inhibitor's conformation, subsite interaction, and hydrogen bonding. The data of geometrical parameters (tau(1), tau(2), and tau(3) listed in Table 2) and root mean square deviation values as compared with the known inhibitor, kni272,(28) show that both kinds of inhibitors interact with HIVPR in a very similar way. The r(2) value of 0.860 indicates that the calculated binding free energies correlate well with the inhibitory activities. The structural and energetic differences in inhibitory potencies of AHPBAs were reasonably explored. Using the binding conformations of AHPBAs, consistent and highly predictive 3D-QSAR models were developed by performing CoMFA, CoMSIA, and HQSAR analyses. The reasonable r(corss)(2) values were 0.613, 0.530, and 0.717 for CoMFA, CoMSIA,and HQSAR models, respectively. The predictive ability of these models was validated by kni272 and a set of nine compounds that were not included in the training set. Mapping these models back to the topology of the active site of HIVPR leads to a better understanding of vital AHPBA-HIVPR interactions. Structural-based investigations and the final 3D-QSAR results provide clear guidelines and accurate activity predictions for novel HIVPR inhibitors.
引用
收藏
页码:333 / 343
页数:11
相关论文
共 56 条
[1]  
Appelt Krzysztof, 1993, Perspectives in Drug Discovery and Design, V1, P23, DOI 10.1007/BF02171654
[2]   STRUCTURE OF HIV-1 PROTEASE WITH KNI-272, A TIGHT-BINDING TRANSITION-STATE ANALOG CONTAINING ALLOPHENYLNORSTATINE [J].
BALDWIN, ET ;
BHAT, TN ;
GULNIK, S ;
LIU, BS ;
TOPOL, IA ;
KISO, Y ;
MIMOTO, T ;
MITSUYA, H ;
ERICKSON, JW .
STRUCTURE, 1995, 3 (06) :581-590
[3]   COMPARATIVE MOLECULAR-FIELD ANALYSIS (COMFA) .1. EFFECT OF SHAPE ON BINDING OF STEROIDS TO CARRIER PROTEINS [J].
CRAMER, RD ;
PATTERSON, DE ;
BUNCE, JD .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1988, 110 (18) :5959-5967
[4]  
Dominy BN, 1999, PROTEINS, V36, P318, DOI 10.1002/(SICI)1097-0134(19990815)36:3<318::AID-PROT6>3.0.CO
[5]  
2-K
[6]   DESIGN, ACTIVITY, AND 2.8 A CRYSTAL-STRUCTURE OF A C2 SYMMETRICAL INHIBITOR COMPLEXED TO HIV-1 PROTEASE [J].
ERICKSON, J ;
NEIDHART, DJ ;
VANDRIE, J ;
KEMPF, DJ ;
WANG, XC ;
NORBECK, DW ;
PLATTNER, JJ ;
RITTENHOUSE, JW ;
TURON, M ;
WIDEBURG, N ;
KOHLBRENNER, WE ;
SIMMER, R ;
HELFRICH, R ;
PAUL, DA ;
KNIGGE, M .
SCIENCE, 1990, 249 (4968) :527-533
[7]  
Frisch M.J., 1998, GAUSSIAN 98
[8]   A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases [J].
Ghose, AK ;
Viswanadhan, VN ;
Wendoloski, JJ .
JOURNAL OF COMBINATORIAL CHEMISTRY, 1999, 1 (01) :55-68
[9]   Quantitative structure-activity relationship studies on cyclic cyanoguanidines acting as HIV-1 protease inhibitors [J].
Gupta, SP ;
Babu, MS .
BIOORGANIC & MEDICINAL CHEMISTRY, 1999, 7 (11) :2549-2553
[10]   4-hydroxy-5,6-dihydropyrones as inhibitors of HIV protease: The effect of heterocyclic substituents at C-6 on antiviral potency and pharmacokinetic parameters [J].
Hagen, SE ;
Domagala, J ;
Gajda, C ;
Lovdahl, M ;
Tait, BD ;
Wise, E ;
Holler, T ;
Hupe, D ;
Nouhan, C ;
Urumov, A ;
Zeikus, G ;
Zeikus, E ;
Lunney, EA ;
Pavlovsky, A ;
Gracheck, SJ ;
Saunders, J ;
VanderRoest, S ;
Brodfuehrer, J .
JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (14) :2319-2332